14 analysts lift Takeda Pharmaceutical stock target to USD 20.74

Takeda Pharmaceutical Company Limited (ISIN US8740602052) was the subject of a higher average analyst target on October 15, 2026. According to TradingView, estimates from 14 analysts lifted the average target from USD 20.58 to USD 20.74. That target is 1.62 percent above the USD 20.41 NYSE quote. Takeda was quoted at USD 20.41 at 11:03 a.m. EDT on October 26, 2026, up 0.84 percent from the USD 20.24 prior close on October 23, 2026.

Results arrive October 29

Takeda's next scheduled investor event is its second-quarter fiscal 2026 earnings announcement on October 29, 2026. The company said the release will be followed by a webcast from 7:00 p.m. to 8:15 p.m. JST. The date gives investors a defined checkpoint for the target revision and for the company's latest operating picture.

The latest quarter beat estimates

MarketBeat reported on October 21, 2026 that Takeda's latest quarterly results included USD 0.95 in earnings per share against a USD 0.41 consensus estimate. Revenue was USD 7.50 billion versus USD 7.13 billion expected, a USD 0.37 billion difference. The same report put the company's market capitalization at USD 64.33 billion and identified the NYSE as its listing venue.

What does the target mean?

The revised USD 20.74 average target leaves a USD 0.33 gap above the October 26 quote. The narrow distance contrasts with the wider USD 16.96 to USD 23.36 range cited for the 14 analyst estimates, so the average masks a broad spread of views.

Dates and valuation matter

Takeda's October 29 release is the next concrete test for the earnings case. The October 15 target update and the USD 0.95 quarterly earnings figure give investors two separate reference points for assessing whether the current USD 20.41 quote is keeping pace with expectations.

Stock position and next update

Takeda's quoted market capitalization was USD 64.95 billion on October 26, 2026. The combination of a USD 20.74 average target, a USD 20.41 market price and the October 29 reporting date keeps the next earnings release central to the near-term stock assessment.

The stock was trading at USD 20.41 on the NYSE at 11:03 a.m. EDT on October 26, 2026, up 0.84 percent from USD 20.24 on October 23, 2026. The further course of trading is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.

Market context: Market report S&P 500.

More news and analyses on Takeda Pharmaceutical stock